These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37986944)

  • 1. FOXO1 is a master regulator of CAR T memory programming.
    Doan A; Mueller KP; Chen A; Rouin GT; Daniel B; Lattin J; Chen Y; Mozarsky B; Markovska M; Arias-Umana J; Hapke R; Jung I; Xu P; Klysz D; Bashti M; Quinn PJ; Sandor K; Zhang W; Hall J; Lareau C; Grupp SA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
    Res Sq; 2023 Nov; ():. PubMed ID: 37986944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXO1 is a master regulator of memory programming in CAR T cells.
    Doan AE; Mueller KP; Chen AY; Rouin GT; Chen Y; Daniel B; Lattin J; Markovska M; Mozarsky B; Arias-Umana J; Hapke R; Jung IY; Wang A; Xu P; Klysz D; Zuern G; Bashti M; Quinn PJ; Miao Z; Sandor K; Zhang W; Chen GM; Ryu F; Logun M; Hall J; Tan K; Grupp SA; McClory SE; Lareau CA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
    Nature; 2024 May; 629(8010):211-218. PubMed ID: 38600391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
    Zheng W; Wei J; Zebley CC; Jones LL; Dhungana Y; Wang YD; Mavuluri J; Long L; Fan Y; Youngblood B; Chi H; Geiger TL
    Blood; 2021 Jul; 138(2):122-135. PubMed ID: 33690816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability.
    Tang J; Sheng J; Zhang Q; Ji Y; Wang X; Zhang J; Wu J; Song J; Bai X; Liang T
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36849200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deleting SUV39H1 in CAR-T cells epigenetically enhances the antitumor function.
    Wang Y; Zhao G; Wang S; Li N
    MedComm (2020); 2024 May; 5(5):e552. PubMed ID: 38645666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming.
    Alvanou M; Lysandrou M; Christophi P; Psatha N; Spyridonidis A; Papadopoulou A; Yannaki E
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death.
    Wang Y; Zhang H; Du G; Luo H; Su J; Sun Y; Zhou M; Shi B; Li HQX; Jiang H; Li Z
    Mol Ther; 2023 Mar; 31(3):701-714. PubMed ID: 36523165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype.
    Alizadeh D; Wong RA; Yang X; Wang D; Pecoraro JR; Kuo CF; Aguilar B; Qi Y; Ann DK; Starr R; Urak R; Wang X; Forman SJ; Brown CE
    Cancer Immunol Res; 2019 May; 7(5):759-772. PubMed ID: 30890531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
    Klebanoff CA; Crompton JG; Leonardi AJ; Yamamoto TN; Chandran SS; Eil RL; Sukumar M; Vodnala SK; Hu J; Ji Y; Clever D; Black MA; Gurusamy D; Kruhlak MJ; Jin P; Stroncek DF; Gattinoni L; Feldman SA; Restifo NP
    JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active Maintenance of T Cell Memory in Acute and Chronic Viral Infection Depends on Continuous Expression of FOXO1.
    Utzschneider DT; Delpoux A; Wieland D; Huang X; Lai CY; Hofmann M; Thimme R; Hedrick SM
    Cell Rep; 2018 Mar; 22(13):3454-3467. PubMed ID: 29590615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors.
    López-Cobo S; Fuentealba JR; Gueguen P; Bonté PE; Tsalkitzi K; Chacón I; Glauzy S; Bohineust A; Biquand A; Silva L; Gouveia Z; Goudot C; Perez F; Saitakis M; Amigorena S
    Cancer Discov; 2024 Jan; 14(1):120-141. PubMed ID: 37934001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
    Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence.
    Wei W; Chen ZN; Wang K
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
    Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
    Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction.
    Jiang P; Zhang Z; Hu Y; Liang Z; Han Y; Li X; Zeng X; Zhang H; Zhu M; Dong J; Huang H; Qian P
    Leukemia; 2022 Nov; 36(11):2656-2668. PubMed ID: 35962059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells.
    Zhang X; Zhang C; Qiao M; Cheng C; Tang N; Lu S; Sun W; Xu B; Cao Y; Wei X; Wang Y; Han W; Wang H
    Cancer Cell; 2022 Nov; 40(11):1407-1422.e7. PubMed ID: 36240777
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype.
    Moreno-Cortes E; Franco-Fuquen P; Garcia-Robledo JE; Forero J; Booth N; Castro JE
    Front Oncol; 2023; 13():1200914. PubMed ID: 37719008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexpression of
    Xu T; Wang C; Chen X; Bai J; Wang E; Sun M
    Immunotherapy; 2022 Dec; 14(18):1457-1466. PubMed ID: 36597720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.